Senseonics SENS 深 滬
等待開盤 07-22 09:30:00 美东时间
5.03
-0.080
-1.57%
華盛通- 最 高5.2599
- 今 開5.13
- 成交量 35.82万股
- 最 低 5.02
- 昨 收 5.11
- 總市值 2.63亿
- 52周最高 11.576
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 4.79
- 委 比 81.90%
- 總股本 5220.30万
- 歷史最高 111.20
- 量 比 0.86
- 振 幅 4.69%
- 歷史最低 4.79
- 每 手 1
- 風險率 1.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Mizuho Maintains Outperform on Senseonics Holdings, Lowers Price Target to $18
Mizuho analyst Anthony Petrone maintains Senseonics Holdings (NASDAQ:SENS) with a Outperform and lowers the price target from $20 to $18.
07-16 02:33
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
Eversense 365 CGM system demonstrated superior performance in both open-loop and closed-loop systems, with strong patient adherence and favorable glucometrics over a full year. The system achieved a mean TIR of 66.16% and GMI of 7.16%, outperforming other CGMs. Integration with the twiist AID system showed promising results, with users achieving a mean TIR of 76.08% and GMI of 6.78%. These findings highlight Eversense 365's exceptional accuracy a...
06-06 21:00
Marathon, Coherent, Senseonics, KLA, Zoetis Insider Shakeup
Insiders have been trading these 5 stocks: (($MPC)), (($COHR)), (($SENS)), (($K...
05-16 21:01
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Stifel Maintains Hold on Senseonics Holdings, Lowers Price Target to $8
Stifel analyst Jonathan Block maintains Senseonics Holdings (NASDAQ:SENS) with a Hold and lowers the price target from $9 to $8.
05-11 21:28
电话会总结 ｜ Senseonics(SENS)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Senseonics业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度净收入达到1,170万美元，较去年同期的630万美元实现85%的强劲增长，主要得益于Eversense 365新患者增长的持续势头以及更多业务转向盈利性更高的捆绑支付渠道。 **利润率情况：** 毛利率达到58%，毛利润为690万美元，较去年同期增加540万美元。排除一次性50万美元的原材料利用收益后，毛利率仍达到约54%的水平。 **亏损状况：** 净亏损为3,230万美元（每股亏损0.71美元），较去年同期的1,430万美元净
05-10 12:09
Senseonics Holdings Raises FY2026 Sales Guidance from $58.000M-$62.000M to $60.000M-$64.000M vs $60.197M Est
Senseonics Holdings (AMEX:SENS) raises FY2026 sales outlook from $58.000 million-$62.000 million to $60.000 million-$64.000 million vs $60.197 million estimate.
05-08 05:47
Senseonics Expands Senior Term Loan Facility to 2029
Senseonics Holdings ( ($SENS) ) has issued an announcement. On May 1, 2026, Sen...
05-05 05:15
